Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep pace, raising questions over its ability to attract and retain the specialized talent needed to sustain its competitiveness. According to…
To read the full story
Related Article
- UA Zensen Manufacturing Wage Hikes at 4.89%, Pharma in Mid-4% Range
September 4, 2026
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Pharma Wage Hikes Seen Settling in Low 4% Range Again: UA Zensen Official
May 21, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Pharma-Cosmetic Union Officially Joins Rengo as Associate Organization
October 9, 2025
- Japanese Pharma-Cosmetic Union Breaks from UA Zensen, Set to Join Rengo
September 25, 2025
- Wage Hikes Average in Low 4% Range, Similar to Last Year: Pharma Labor Group
August 28, 2025
COMMENTARY
- Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
October 6, 2026
- Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
September 28, 2026
- Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
September 15, 2026
- As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
- Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
September 3, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…